Navigation Links
Adeona Announces Third Quarter 2010 Financial Results and Achievements
Date:11/15/2010

will be available for replay at www.adeonapharma.com for a period of at least 30 days after the call.

"We continue to make excellent progress in the clinical development of our product candidates for Alzheimer's disease and multiple sclerosis.  With patient enrollment now complete in the Alzheimer's disease clinical study, we expect to report top-line results after all patients have completed their 6 month follow-up, anticipated to occur toward the end of March 2011. In parallel with this ongoing clinical study, we are working to make Zinthionein commercially available as a prescription medical food," stated James S. Kuo, M.D., M.B.A., Adeona's Chief Executive Officer. "We are also encouraged by the continued growth of the client base, net revenues and the expanded testing services offered at Adeona Clinical Laboratory."

About Adeona Pharmaceuticals, Inc.

Adeona is a pharmaceutical company developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Currently, Adeona has the following product candidates in development: a prescription medical food for Alzheimer's disease, and four drugs for multiple sclerosis, fibromyalgia, rheumatoid arthritis and dry age-related macular degeneration. For more information, please visit Adeona's website at www.adeonapharma.com.

This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements a
'/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Adeona Announces HartLab Expansion Into Microbiology Testing Services
2. Adeona Completes Equity Financing and Provides Alzheimers Disease Clinical Study Update
3. Adeona Announces Second Quarter 2010 Profitability and Achievements
4. Adeona Announces Five Scientific Publications on Role of Copper Toxicity and Zinc Deficiency in Alzheimers Disease and Cognitive Decline
5. Adeona CEO to Provide Keynote Address at the 2010 MichBio Expo & Conference Emerging Biosciences Showcase
6. Adeona to Hold Annual Shareholder Meeting
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... Moerae Matrix, a clinical stage biotechnology ... inflammation and fibrosis, today announced the appointment of ... Medical Officer. Dr. Bradford will ... which include a pipeline of therapies for pulmonary ... is an accomplished strategist and scientist with extensive ...
(Date:7/6/2015)... , July 6, 2015 Celtaxsys, Inc., a ... including those with rare and orphan inflammatory disease indications, ... U.S. Food and Drug Administration (FDA) to begin a ... acebilustat (CTX-4430), in adult CF patients in the US. ... Europe will be filed soon after. ...
(Date:7/6/2015)... --  Cepheid (Nasdaq: CPHD ) today announced that ... quarter ended June 30, 2015 on Thursday, July 23, ... The Company will host a management presentation at 2 ... discuss the results.  To access the live webcast, please ... 15 minutes before the scheduled start time to download ...
Breaking Medicine Technology:Moerae Matrix, Inc. (Moerae) Appoints Bill Bradford, M.D., PhD, as Chief Medical Officer 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3
... 2011 VolitionRX Limited ("Volition") (VNRX.OB), ... diagnostic tests, is pleased to announce that its ... signed a contract which is expected to provide ... commissioned to develop epigenetic profiling signatures from blood. ...
... Technology Services successfully implemented advanced process technology for ... in Shanghai, China, using Intergraph® integrated design and ... solvent and energy consumption as well as operating ... http://photos.prnewswire.com/prnh/20081211/DECLOGO) These results are achieved, among ...
Cached Medicine Technology:VolitionRX Subsidiary Enters Into its First Revenue-Generating Agreement to Profile Blood-Based Epigenetic Signatures 2VolitionRX Subsidiary Enters Into its First Revenue-Generating Agreement to Profile Blood-Based Epigenetic Signatures 3Intergraph® Technology Enables Bayer Technology Services to Engineer New Plant in China 2Intergraph® Technology Enables Bayer Technology Services to Engineer New Plant in China 3
(Date:7/6/2015)... Rancho Cucamonga, Ca (PRWEB) , ... July 06, 2015 , ... ... two distinguished awards in 2015, marking him as an attorney who has ... Fernando Vargas received both a Client Distinction Award for 2015 from Martindale-Hubbell and a ...
(Date:7/6/2015)... ... , ... University of Pittsburgh Cancer Institute (UPCI) scientists recently led ... newly available tests that better incorporate personalized medicine into diagnosing the condition. , ... is published in the July issue of the scientific journal Thyroid . ...
(Date:7/6/2015)... ... July 06, 2015 , ... Shortly after opening her ... the leading network of doctors working on a lien basis. Dr. Lim had ... , The daughter of two Cambodian refugees, Dr. Lim suffered with back pain herself ...
(Date:7/6/2015)... Virginia (PRWEB) , ... July 06, 2015 , ... ... choose fat-reduction procedures each year for aesthetic reasons, which is why liposuction regularly ... For a particular demographic, however, fat reduction has become more than a way ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... for radiology services and ADVOCATE is leading the transition. ADVOCATE, the only 100% ... with their Top 10 Tips for ICD-10. The ten tips are timely and ...
Breaking Medicine News(10 mins):Health News:Fernando D. Vargas Awarded Top Honors in Personal Injury Law for 2015 from Two Respected Independent Organizations 2Health News:Fernando D. Vargas Awarded Top Honors in Personal Injury Law for 2015 from Two Respected Independent Organizations 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 5Health News:Respected Chiropractor Opens Office in Signal Hill/Cambodia Town and Joins Doctors on Liens 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3Health News:ADVOCATE Takes the Lead to Ensure ICD-10 Success: “Top 10 Tips for ICD-10” 2
... for Everyone , Not all patients can tolerate ... can help physicians calculate the epirubicin dose associated with ... , Oncologists frequently use anthracyclines, including epirubicin and doxorubicin, ... lasting heart problems in a substantial number of patients. ...
... 6.9 percent sequentially - Q2 GAAP net profit ... - Case shipments of 54,870 increase 6.0 percent sequentially ... SANTA CLARA, Calif., July 29 Align,Technology, Inc. (Nasdaq: ALGN ... ended June 30, 2008., Total net revenues for the second ...
... projected ... ... of,high-quality ceramic solutions for the medical device industry, announced,today that, in ... on unit shipments to the orthopaedic,brachytherapy and electro-implantable market segments., ...
... FACP, FACEP (E), Executive,Director, American Public Health Association, ... Association strongly urges U.S. House members to vote ... Food and Drug Administration (FDA),the authority to regulate ... for more than 400,000 deaths each,year and costs ...
... of matted protein, researchers say , , TUESDAY, July 29 (HealthDay ... clogging "tangles" in the brain cells of people with Alzheimer,s ... studies are necessary to confirm whether the medication is as ... needs to be given as part of a cocktail of ...
... ... Future Costs Can Be Avoided with Proper Treatment and Prevention ... Initiatives, NEW BRUNSWICK, N.J., ... on New,Jersey,s economy of the most common chronic diseases is calculated to be,$39 billion. In ...
Cached Medicine News:Health News:Also in the July 29 JNCI 2Health News:Also in the July 29 JNCI 3Health News:Also in the July 29 JNCI 4Health News:Also in the July 29 JNCI 5Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 2Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 3Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 4Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 5Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 6Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 7Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 8Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 9Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 10Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 11Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 12Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 13Health News:C5 Medical Werks Reaches Million Mark in Components Shipped 2Health News:'De-Tangling' Alzheimer's Drug Shows Promise 2Health News:'De-Tangling' Alzheimer's Drug Shows Promise 3Health News:'De-Tangling' Alzheimer's Drug Shows Promise 4Health News:Annual Economic Impact of Chronic Disease on New Jersey Economy Is $39 Billion 2Health News:Annual Economic Impact of Chronic Disease on New Jersey Economy Is $39 Billion 3Health News:Annual Economic Impact of Chronic Disease on New Jersey Economy Is $39 Billion 4
Inquire...
Superior imaging through a 410,000 pixel CCD, unseen color replication from a digital signal processor in the scope, and the added benefit of four way tip deflection make the TF410 a superior choice ...
The computer-optimized optical design produces large, brilliant images of high resolution....
ACMI™ Distortion-Free Laparoscopes utilize technical advances in optical lens design to provide images without the fish-eye effect typically found on the peripheral viewing edges of conventional...
Medicine Products: